DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "CD19 Therapeutics Market, 2016 - 2030" report to their offering.
One of the key objectives of the study is to review and quantify the opportunities laid by the innovative CD19 targeted programs of both small and big pharma firms. Amongst other elements, the report elaborates upon the following key areas:
- The current state of the market with respect to key players, developmental stages of pipeline products (both clinical/preclinical) and target indications
- Partnerships that have taken place in the recent past covering research and development collaborations, manufacturing agreements and license agreements specific to technology platforms, product co-development and co-commercialization
- Competitive landscape and inherent threats to growth in the short and long term
The study provides an estimate of the short-mid term and long term market forecast for the period 2015 - 2030. The research, analysis and insights presented in this report include potential sales of various marketed and late stage (phase II and phase II/III) anti-CD19 products based on our understanding of the likely future development of individual therapeutics. The opinions and insights, presented in this study, were influenced by discussions that we conducted with experts in this area.
Owing to niche nature of the market, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.
Companies Mentioned Include:
- AbDSerotec
- Amphivena
- ADC Therapeutics
- Advaxis
- AIMM Therapeutics
- BioWa
- Bluebird Bio
- BoehringerIngelheim
- Formula Pharmaceuticals
- Fred Hutchinson Cancer Research Center
- Fuda Cancer Hospital
- Galapagos
- Ohio State University
- OncoMed
- Southwest Hospital
- Swedish Cancer Society
-
Takara Bio
Report Structure:
1. Preface
2. Executive Summary
3. Introduction
4. Market Overview
5. Chimeric Antigen Receptor-T Cell Therapies
6. Engineered Antibodies
7. Bispecific Antibodies
8. Antibody Drug Conjugates (ADCs)
9. Key Therapeutic Areas
10. Market Forecast
11. Conclusion
12. Interview Transcripts
For more information visit http://www.researchandmarkets.com/research/62frjr/cd19_therapeutics
